Recent advances in oral anticancer agents for colon cancer
作者： Raj Kumar Shukla
DOI: 10.2217/FON.13.137
关键词: Irinotecan 、 Eflornithine 、 Colorectal cancer 、 Sulindac 、 Oncology 、 Camptothecin 、 Chemotherapy 、 Rubitecan 、 Internal medicine 、 Medicine 、 Pharmacology 、 Oxaliplatin
摘要: To provide therapeutic alternatives to intravenous colon chemotherapy major recent research is focusing on the development of oral chemotherapeutic agents with intention improve quality life patients. Initially 5-fluorouracil was most commonly used for treatment colorectal cancer but currently oxaliplatin and irinotecan are also available. The majority these new drugs pyrimidines their analogs. rationale using anticancer discussed drugs, such as farnesyl protein transferase inhibitor S-1, rubitecan, ZD9331, MMI-166, eflornithine, sulindac, camptothecin analogs, among others, presented results preclinical clinical developments. This article focuses advancement discusses relative merits demerits agents. accelerated approval by regulatory authorities supported survival benefit, response rate time progression.
futuremedicine.com
sci-hub.se 参考文章(56)
Maja J.A. de Jonge, Cornelis J.A. Punt, Alex Sparreboom, André S.T. Planting, M.E.W.J. Peters, Jacqueline van de Schraaf, Ann Jackman, Rob Smith, Pieter H.M. de Mulder, Jaap Verweij, Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors Journal of Clinical Oncology. ,vol. 20, pp. 1923- 1931 ,(2002) , 10.1200/JCO.2002.07.057
Patrick Gleason, Catherine I. Starner, Brent W. Gunderson, Jeremy A. Schafer, H. Scott Sarran, Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. Journal of Managed Care Pharmacy. ,vol. 15, pp. 648- 658 ,(2009) , 10.18553/JMCP.2009.15.8.648
David R Fogelman, Scott Kopetz, Cathy Eng, Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs. ,vol. 13, pp. 629- 642 ,(2008) , 10.1517/14728210802544575
S Rao, David Cunningham, A De Gramont, W Scheithauer, M Smakal, Y Humblet, G Kourteva, T Iveson, T Andre, J Dostalova, A Illes, R Belly, JJ Perez-Ruixo, YC Park, PA Palmer, None, Phase III Double-Blind Placebo-Controlled Study of Farnesyl Transferase Inhibitor R115777 in Patients With Refractory Advanced Colorectal Cancer Journal of Clinical Oncology. ,vol. 22, pp. 3950- 3957 ,(2004) , 10.1200/JCO.2004.10.037
Kouji Oba, Hiroyuki Konno, Tatsuo Tanaka, Megumi Baba, Kinji Kamiya, Manabu Ohta, Takeshi Kaneko, Tsuyoshi Shouji, Akira Igarashi, Satoshi Nakamura, Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166. Cancer Letters. ,vol. 175, pp. 45- 51 ,(2002) , 10.1016/S0304-3835(01)00726-1
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, Dirk Laurent, None, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial The Lancet. ,vol. 381, pp. 303- 312 ,(2013) , 10.1016/S0140-6736(12)61900-X
Gregory B. Kruse, Mayur M. Amonkar, Gregory Smith, Dean C. Skonieczny, Spyros Stavrakas, Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. Journal of Managed Care Pharmacy. ,vol. 14, pp. 844- ,(2008) , 10.18553/JMCP.2008.14.9.844
Valerie Boige, Alain Gouyette, Sylvie Zanetta, Alain Deroussent, Alexandre Santos, Gilles Vassal, Laurent Vernillet, Eric Raymond, Marie-Laure Risse, Thierry Cresteil, François Pein, Metabolism of Irinotecan (CPT-11) by CYP3A4 and CYP3A5 in Humans Clinical Cancer Research. ,vol. 6, pp. 2012- 2020 ,(2000)
Fabian T. Camacho, Jun Wu, Wenhui Wei, Gretchen Kimmick, Roger T. Anderson, Rajesh Balkrishnan, Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer Journal of Medical Economics. ,vol. 12, pp. 238- 245 ,(2009) , 10.3111/13696990903269673
William C Zamboni, Laura L Jung, Merrill J Egorin, Deborah R Hamburger, Erin Joseph, Ruzhi Jin, Sandra Strychor, Ramesh K Ramanathan, Julie L Eiseman, Relationship between Plasma Exposure of 9-Nitrocamptothecin and Its 9-Aminocamptothecin Metabolite and Antitumor Response in Mice Bearing Human Colon Carcinoma Xenografts Clinical Cancer Research. ,vol. 11, pp. 4867- 4874 ,(2005) , 10.1158/1078-0432.CCR-05-0144